Overview

A Phase 1 Clinical Trial of Siltuximab for the Treatment of Antibody-Mediated Rejection After Lung Transplantation

Status:
NOT_YET_RECRUITING

Trial end date:
2028-06-30

Target enrollment:

Participant gender:

Summary

Antibody-mediated rejection after lung transplantation commonly results in allograft failure and death in spite of current therapeutic regimens. We are testing the safety and tolerability of the addition of a novel immunosuppressive medication to routine treatment for antibody-mediated rejection. Future studies will be needed to assess efficacy if this study demonstrates safety

Phase:

PHASE1

Details

Lead Sponsor:

Washington University School of Medicine

Collaborators:

National Heart, Lung, and Blood Institute (NHLBI)
University of Utah

Treatments:

siltuximab